Samsung Biologics Co.,Ltd.
207940
Pozycja w akcjach
#496
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Cena akcji
$1,028.49
Kapitalizacja rynkowa
$47.88B
Zmiana (1 dzień)
-3.67%
Zmiana (1 rok)
-18.37%
Kraj
KR
Handel Samsung Biologics Co.,Ltd. (207940)
Kategoria
Healthcare
Zyski dla Samsung Biologics Co.,Ltd. (207940)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Samsung Biologics Co.,Ltd., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Samsung Biologics Co.,Ltd. od 2014 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2025 | $1.47B | 55.69% |
| 2024 | $941.97M | 8.88% |
| 2023 | $865.17M | 8.20% |
| 2022 | $799.60M | 69.37% |
| 2021 | $472.11M | 92.69% |
| 2020 | $245.01M | 82.02% |
| 2019 | $134.61M | -50.53% |
| 2018 | $272.09M | -350.00% |
| 2017 | $-108.84M | -43.17% |
| 2016 | $-191.50M | -109.05% |
| 2015 | $2.12B | -2,423.97% |
| 2014 | $-91.10M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $3.01B | - |
BE
|
|
| $1.95B | - |
NL
|
